-
Something wrong with this record ?
The safety of neoadjuvant hormonal treatment in infants with cryptorchidism
V. Fiala, Z. Jiraskova, M. Drlik, J. Sedlacek, Z. Dite, P. Novakova, R. Kocvara, M. Kalousova, V. Soukup
Language English Country England, Great Britain
Document type Journal Article, Randomized Controlled Trial
- MeSH
- Follicle Stimulating Hormone MeSH
- Gonadotropin-Releasing Hormone MeSH
- Infant MeSH
- Cryptorchidism * drug therapy surgery MeSH
- Humans MeSH
- Neoadjuvant Therapy MeSH
- Prospective Studies MeSH
- Testis diagnostic imaging surgery pathology MeSH
- Testosterone MeSH
- Check Tag
- Infant MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
BACKGROUND/PURPOSE: The standard treatment for boys with non-syndromic cryptorchidism is an early orchidopexy. It is unclear if surgical intervention alone is enough for future fertility. Recent studies show benefit of neoadjuvant or adjuvant hormonal treatment with gonadorelin (GnRH) for spermatogonia maturation based on testicular biopsy. The aim of this prospective study was to assess the safety of this treatment in infants with undescended testis at the recommended timing of early gonadorelin administration and timing of orchidopexy. METHODS: Unilateral cryptorchid full term boys were initially examined (including hormonal, physical and ultrasound examination) at the age of 2.5-3.5 months. At 6 months of age, cryptorchidism was confirmed. Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment. Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups). The following orchidopexy was performed before 12 months of age with repeated examination at time of surgery. Penile size and testicular volume (using ultrasound) and basal serum levels of LH, FSH, testosterone, Inhibin B and AMH were recorded at age of 3.0 (mean) months and 11.0 (mean) months (date of surgery). The stimulation hormonal levels were checked during GnRH administration. RESULTS: Between minipuberty (mean 3 months) and time of orchidopexy (mean 11 months of age) the penile size increased significantly and similarly in both groups. There was no significant difference in the change of the volume of descended testis between the groups nor of the volume of undescended testis. In addition, we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a) CONCLUSION: The neoadjuvant gonadorelin stimulation in infants with unilateral undescended testis has not shown any specific effect on the development of penile size, testicular volume and hormonal levels at time of orchidopexy in comparison with boys without stimulation, and in the mid-term, this treatment can be considered safe. Further follow-up is necessary to evaluate the long-term effect of this early treatment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032506
- 003
- CZ-PrNML
- 005
- 20230131151521.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpurol.2022.05.010 $2 doi
- 035 __
- $a (PubMed)35691791
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Fiala, Vojtech $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: vojtech.fiala@vfn.cz
- 245 14
- $a The safety of neoadjuvant hormonal treatment in infants with cryptorchidism / $c V. Fiala, Z. Jiraskova, M. Drlik, J. Sedlacek, Z. Dite, P. Novakova, R. Kocvara, M. Kalousova, V. Soukup
- 520 9_
- $a BACKGROUND/PURPOSE: The standard treatment for boys with non-syndromic cryptorchidism is an early orchidopexy. It is unclear if surgical intervention alone is enough for future fertility. Recent studies show benefit of neoadjuvant or adjuvant hormonal treatment with gonadorelin (GnRH) for spermatogonia maturation based on testicular biopsy. The aim of this prospective study was to assess the safety of this treatment in infants with undescended testis at the recommended timing of early gonadorelin administration and timing of orchidopexy. METHODS: Unilateral cryptorchid full term boys were initially examined (including hormonal, physical and ultrasound examination) at the age of 2.5-3.5 months. At 6 months of age, cryptorchidism was confirmed. Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment. Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups). The following orchidopexy was performed before 12 months of age with repeated examination at time of surgery. Penile size and testicular volume (using ultrasound) and basal serum levels of LH, FSH, testosterone, Inhibin B and AMH were recorded at age of 3.0 (mean) months and 11.0 (mean) months (date of surgery). The stimulation hormonal levels were checked during GnRH administration. RESULTS: Between minipuberty (mean 3 months) and time of orchidopexy (mean 11 months of age) the penile size increased significantly and similarly in both groups. There was no significant difference in the change of the volume of descended testis between the groups nor of the volume of undescended testis. In addition, we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a) CONCLUSION: The neoadjuvant gonadorelin stimulation in infants with unilateral undescended testis has not shown any specific effect on the development of penile size, testicular volume and hormonal levels at time of orchidopexy in comparison with boys without stimulation, and in the mid-term, this treatment can be considered safe. Further follow-up is necessary to evaluate the long-term effect of this early treatment.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a kryptorchismus $x farmakoterapie $x chirurgie $7 D003456
- 650 _2
- $a folikuly stimulující hormon $7 D005640
- 650 _2
- $a hormon uvolňující gonadotropiny $7 D007987
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a testis $x diagnostické zobrazování $x chirurgie $x patologie $7 D013737
- 650 _2
- $a testosteron $7 D013739
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Jiraskova, Zuzana $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: valova.z@gmail.com
- 700 1_
- $a Drlik, Marcel $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: marcel.drlik@vfn.cz
- 700 1_
- $a Sedlacek, Josef $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: josef.sedlacek@vfn.cz
- 700 1_
- $a Dite, Zdenek $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: zdenek.dite@vfn.cz
- 700 1_
- $a Novakova, Petra $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: petra.novakova2@vfn.cz
- 700 1_
- $a Kocvara, Radim $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: radim.kocvara@vfn.cz
- 700 1_
- $a Kalousova, Marta $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: marta.kalousova@lf1.cuni.cz
- 700 1_
- $a Soukup, Viktor $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: viktor.soukup@vfn.cz
- 773 0_
- $w MED00166989 $t Journal of pediatric urology $x 1873-4898 $g Roč. 18, č. 6 (2022), s. 846.e1-846.e6
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35691791 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151517 $b ABA008
- 999 __
- $a ok $b bmc $g 1891330 $s 1183841
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 18 $c 6 $d 846.e1-846.e6 $e 20220519 $i 1873-4898 $m Journal of pediatric urology $n J Pediatr Urol $x MED00166989
- LZP __
- $a Pubmed-20230120